Introducing: Stefanie Kammerman, Legendary Dark Pool Trader

For the 1st time ever, a former financial insider is stepping forward to show you how to spot Wall Street’s “hidden” trades before they move the market.

Wed, July 15 at 7:00PM ET
 
 
 
 

27 Biotechnology Stocks to Sell Now

27 Biotechnology Stocks to Sell Now

The ratings of 27 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Intercept Pharmaceuticals, Inc. (ICPT) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

This week, Incyte Corporation (INCY) drops from a C to a D rating. Incyte Corporation is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Alnylam Pharmaceuticals, Inc (ALNY) declines this week from a D to a F. Alnylam Pharmaceuticals, Inc engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). The company also gets F’s in sales growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ALNY stock.

Slipping from a C to a D rating, Eagle Pharmaceuticals, Inc. (EGRX) takes a hit this week. The company also gets F’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of EGRX stock.

Ionis Pharmaceuticals, Inc. (IONS) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in sales growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of IONS stock.

Spark Therapeutics, Inc. (ONCE) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of ONCE stock.

AMAG Pharmaceuticals, Inc. (AMAG) slips from a D to a F this week. AMAG Pharmaceuticals, Inc. utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company also gets F’s in operating margin growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMAG stock.

Mirati Therapeutics Inc.’s (MRTX) rating weakens this week, dropping to a D versus last week’s C. Mirati Therapeutics Inc. engages in the development of therapeutics for the treatment of cancer. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRTX stock.

Blueprint Medicines Corp. (BPMC) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BPMC stock.

This week, Aduro BioTech, Inc.’s (ADRO) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of ADRO stock.

This is a rough week for Concert Pharmaceuticals, Inc. (CNCE). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CNCE stock.

Epizyme, Inc. (EPZM) slips from a C to a D this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

Tobira Therapeutics, Inc. (TBRA) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TBRA stock.

Proteon Therapeutics, Inc. (PRTO) declines this week from a C to a F. The company also gets F’s in earnings growth, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTO stock.

This is a rough week for Tokai Pharmaceuticals, Inc. (TKAI). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TKAI stock.

Slipping from a C to a D rating, Sorrento Therapeutics, Inc. (SRNE) takes a hit this week. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of SRNE stock.

Chimerix, Inc. (CMRX) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CMRX stock.

This week, Galmed Pharmaceuticals Ltd.’s (GLMD) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GLMD stock.

Calithera Biosciences, Inc. (CALA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CALA stock.

Trovagene, Inc.’s (TROV) rating weakens this week, dropping to a D versus last week’s C. Trovagene, Inc. is developing a non-invasive testing technology using transrenal nucleic acid (TrNA) markers for infectious diseases, prenatal testing, early detection of cancer, and monitoring of organ and cell transplantation. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TROV stock.

Aurinia Pharmaceuticals Inc. (AUPH) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

This week, Abeona Therapeutics, Inc. (ABEO) drops from a B to a F rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ABEO stock.

This week, Corbus Pharmaceuticals Holdings Inc’s (CRBP) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of CRBP stock.

Tonix Pharmaceuticals Holding Corp. (TNXP) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TNXP stock.

This week, Curis, Inc. (CRIS) drops from a C to a D rating. Curis, Inc. is a drug discovery and development company that engages in the research and development of cancer therapeutics. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

This is a rough week for Fate Therapeutics, Inc. (FATE). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FATE stock.

Galectin Therapeutics Inc. (GALT) is having a tough week. The company’s rating falls from a D to a F. Galectin Therapeutics Inc. is a drug development company. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GALT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/05/27-biotechnology-stocks-to-sell-now/.

©2020 InvestorPlace Media, LLC